Integrity Bio Announces Newly Validated Biotech Medicine Manufacturing Line Doubling Fill/Finish Capacity

Thousand Oaks, Calif., 6/9/2020:  Integrity Bio announced the validation of its second fill/finish manufacturing line.  This plant expansion more than doubles the company’s manufacturing capacity to meet growing demand in the field.

Founded in 2003, Integrity Bio has established itself as a premier provider of Formulation Development, GMP Fill Finish Services, and Innovative Drug Delivery technologies to support biotechnology and pharmaceutical companies large and small who strive to save or improve the quality of human life through innovative medicine.

“Customer demand for our fill/finish services drove us to make the investment in a brand-new manufacturing line,” said Michael Reilly, CEO of Integrity Bio.  “The validation timing could not have been better.  The new capacity allows us to prioritize COVID-19 projects.  I’m really proud of all the hard work our team put into this project to get it to the finish line.”

Geno Worke, Senior Director of Operations added, “We are really excited about this second line.  It complements our first line by integrating a number of key new features that customers have asked for, such as a restricted access barrier system (aka RABS), and increased speed with an automatic vial washing and depyrogenation tunnel attached.  The new line allows us to fill over 20,000 liquid vials in a single batch which obviously means we can handle bigger projects for our clients.”

Integrity Bio specializes in biologics formulation development and drug product manufacturing and has formulated over 200 biologics including vaccines, antibodies, proteins, and peptides for more than 150 firms ranging from Fortune 500 biotech companies to virtual start-ups. The company has expertise in hard-to-formulate products in liquid and lyophilized forms.

A day trip from most West Coast cities, Integrity Bio is located in Thousand Oaks and Camarillo, California, the center of a highly concentrated cluster of over 5,000 biotech professionals. Demand for their research services increased by 30% in the past year, driving continued expansion.